Navigation Links
AstraZeneca's Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Date:1/27/2009

Differences in Prescribing Patterns Were Observed Between U.S. and European Oncologists, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that AstraZeneca's zibotentan will become Decision Resources' proprietary clinical gold standard by 2012 and through 2017 for the treatment of metastatic hormone-refractory prostrate cancer due to its competitive advantages in overall efficacy, safety and tolerability and delivery measures over the current gold standard, Sanofi-Aventis' Taxotere. Zibotentan also has a significant advantage in terms of delivery over all current and emerging therapies because it is likely to be used as an oral monotherapy.

"Interviewed key opinion leaders' optimism for zibotentan's Phase II survival data combined with our survey results make zibotentan the most likely agent to supplant Sanofi-Aventis' Taxotere as our gold standard treatment for metastatic hormone-refractory prostate cancer patients," stated Natalia Reoutova, M.Sc., analyst at Decision Resources.

The new report entitled Metastatic Hormone-Refractory Prostate Cancer: Physicians Optimistic About Targeted Therapies also finds that significant differences were observed between U.S. and European oncologists' prescribing patterns, which highlight European oncologists' greater price sensitivity compared to their U.S. counterparts.

About the Report

Metastatic Hormone-Refractory Prostate Cancer: Physicians Optimistic About Targeted Therapies is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

<
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur!
2. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
3. Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador
4. Zumas Rescue Ranch becomes a Federal 501C3
5. MinuteClinic Becomes Participating Provider With Blue Cross and Blue Shield of Florida
6. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
7. Dental Network of America Becomes Largest National Dental Network in the U.S.
8. Mega Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain
9. When the Caregiver Becomes the Patient
10. K-State helps nursing home staff become comfortable with residents sexual expression
11. 26 percent of sleepless children become overweight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... ECC ... first neighborhood created specifically for adults with intellectual, developmental and acquired disabilities. The ... and feature 30 cottage or “pocket” homes. In this community, adults will live ...
(Date:9/4/2015)... ... 04, 2015 , ... FiltersFast.com, the online retail leader in ... passed up. FiltersFast.com, will ship all orders over $50.00 for free. Use ... Take advantage of this promotion now through September 8, 2015. , Filtersfast.com offers ...
(Date:9/3/2015)... Calif. (PRWEB) , ... September 03, 2015 , ... Allied ... Fullerton, where innovative medicine is the norm not the exception. , St. Jude was ... the American Heart Association/American Stroke Association, making it one of only 10 hospitals in ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... Inc., a leading national healthcare solutions organization, to provide electronic medical record (EMR) ... this agreement, Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR ...
(Date:9/3/2015)... Newport, RI (PRWEB) , ... September 03, 2015 , ... ... for beds, the BedJet v2, for pre-order on Kickstarter. Today the BedJet v2 ... placing it in the top 0.1% most successful campaigns ever on crowdfunding giant Kickstarter. ...
Breaking Medicine News(10 mins):Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3
... showed improved outcomes as compared with bare,metal stents ... were found with drug-eluting stents in,diabetic patients., ... risk of revascularization, heart attack and death in ... observational comparison,researchers reported at the American Heart Association,s ...
... ORLEANS, Nov. 11 A veteran medical,correspondent ... Howard L.,Lewis Achievement Award for excellence in ... of Freemont, Calif., was honored for "his ... economic,political, ethical and cultural implications of cardiovascular ...
... that can lead to breast cancer could be one step ... the charity Breast Cancer Campaign to fill in one of ... experts in a recent study carried out by the charity. ... to be involved in the early stages of breast cancer. ...
... Researchers at the University of Exeter have found that ... cravings. The benefits of exercise in helping people manage ... recognised. Now, for the first time, newly-published research shows ... , Following three days of abstinence, 25 regular chocolate ...
... Corporate and Employee Commitment to CourionCares,Philanthropy Program Aids ... Nov. 11 Courion(R) Corporation,leaders in access assurance ... citizenship program, has raised more,than $100,000 in support ... eighth annual charity auction held on Friday, Nov. ...
... Misonix, Inc.,(Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and,worldwide ... to,release first quarter fiscal year 2009 financial results ... President and Chief,Executive Officer and Richard Zaremba, Senior ...
Cached Medicine News:Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 2Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 3Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 4Health News:New technique to study the genetics of breast cancer 2Health News:Brisk walk could help chocoholics stop snacking 2Health News:Courion Exceeds $100,000 Charitable Giving Milestone with Eighth Annual Employee Fundraiser 2Health News:Courion Exceeds $100,000 Charitable Giving Milestone with Eighth Annual Employee Fundraiser 3Health News:Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern 2
(Date:9/4/2015)... , Sep. 04, 2015 ... has announced the addition of the "Veterinary ... December 7-8, 2015)" conference to their offering. ... participants through all of the constituent parts of ... medicinal product for which a marketing authorisation is ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
(Date:9/3/2015)... a population of more than 1 billion, China is ... largest potential market for goods and services. In the ... economies in the average rate of growth in real ... an in vitro diagnostics (IVD) market, China trails only ... European countries, and Japan. China represents one of the ...
Breaking Medicine Technology:Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... 20 Sanofi-aventis (EURONEXT: SAN and NYSE: ... at the European Association for the Study of Diabetes ... pooled analysis using patient-level data from randomized clinical trials ... patients with type 2 diabetes, uncontrolled on oral antidiabetic ...
... Biotechnology Corporation (Nasdaq: GNBT ), ( www.generex.com ... through the inner lining of the mouth, today announced ... Elias Shaker & Company ( www.eliasshaker.com ), a leading ... novel consumer products to national and regional retail and ...
Cached Medicine Technology:Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes 2Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes 3Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes 4Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes 5Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes 6Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes 7Generex Announces Sales Agreement with Elias Shaker & Company 2Generex Announces Sales Agreement with Elias Shaker & Company 3Generex Announces Sales Agreement with Elias Shaker & Company 4
1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
... units Pen.,10k ug Strept. 25 ... Culture Reagent and Buffer products ... cGMP regulations and are cell ... , Typical Properties, Sterility : ...
... Penicillin/25,000 ug Streptomycin All ... Buffer products are manufactured in ... are cell culture tested to ... Sterility : Neg. , pH ...
Medicine Products: